
Osmotica Pharmaceuticals plc OSMT
Country |
|
IPO year |
2018 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
62.8 M |
Market Cap[1] |
$ 89.9 M |
EBITDA (LTM) |
$ 488 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Neos Therapeutics, Inc.
NEOS
|
- | -2.54 % | $ 57.2 M | Nasdaq Global Market | ||
|
Xenetic Biosciences
XBIO
|
$ 1.52 | -5.59 % | $ 2.59 M | Nasdaq Capital Market | ||
|
Odonate Therapeutics, Inc.
ODT
|
- | -3.18 % | $ 58.5 M | Nasdaq Global Select Market | ||
|
Orphazyme A/S
ORPH
|
- | -2.25 % | $ 31.3 M | Nasdaq Global Select Market | ||
|
Pandion Therapeutics, Inc.
PAND
|
- | - | $ 1.77 B | Nasdaq Global Select Market | ||
|
Xenon Pharmaceuticals
XENE
|
$ 37.93 | -2.19 % | $ 3.01 B | Nasdaq Global Select Market | ||
|
Xeris Pharmaceuticals
XERS
|
$ 16.95 | 0.92 % | $ 2.72 B | Nasdaq Global Select Market | ||
|
22nd Century Group
XXII
|
$ 0.38 | -14.05 % | $ 69.9 K | NYSE American | ||
|
Translate Bio, Inc.
TBIO
|
- | - | $ 2.81 B | Nasdaq Global Select Market,SPB | ||
|
Trillium Therapeutics Inc.
TRIL
|
- | - | $ 1.94 B | Nasdaq Capital Market | ||
|
Urovant Sciences Ltd.
UROV
|
- | - | $ 532 M | Nasdaq Global Select Market | ||
|
Acceleron Pharma Inc.
XLRN
|
- | - | $ 10.9 B | Nasdaq Global Market,SPB | ||
|
Zealand Pharma A/S
ZEAL
|
- | 0.52 % | $ 821 M | Nasdaq Global Select Market | ||
|
Zogenix, Inc.
ZGNX
|
- | -4.97 % | $ 664 M | Nasdaq Global Market,SPB | ||
|
Yunhong International
ZGYH
|
- | 0.10 % | $ 92.2 M | Nasdaq Capital Market | ||
|
ZIOPHARM Oncology, Inc.
ZIOP
|
- | -7.58 % | $ 264 M | Nasdaq Global Select Market | ||
|
Taysha Gene Therapies
TSHA
|
$ 3.99 | -0.25 % | $ 1.28 B | Nasdaq Global Select Market | ||
|
Zentalis Pharmaceuticals
ZNTL
|
$ 1.38 | -7.38 % | $ 99.2 M | Nasdaq Global Market | ||
|
Zoetis
ZTS
|
$ 85.52 | 2.44 % | $ 37.9 B | NYSE,SPB | ||
|
Vanda Pharmaceuticals
VNDA
|
$ 3.76 | -1.44 % | $ 222 M | Nasdaq Global Select Market,SPB | ||
|
Vericel Corporation
VCEL
|
$ 58.63 | 1.29 % | $ 2.95 B | Nasdaq Global Select Market,SPB | ||
|
Veracyte
VCYT
|
$ 25.54 | 5.41 % | $ 2.01 B | Nasdaq Global Market,SPB | ||
|
VistaGen Therapeutics
VTGN
|
$ 0.2 | 5.69 % | $ 7.61 M | Nasdaq Global Select Market | ||
|
Viking Therapeutics
VKTX
|
$ 26.19 | -2.59 % | $ 2.95 B | Nasdaq Capital Market | ||
|
Voyager Therapeutics
VYGR
|
$ 1.68 | 10.2 % | $ 98.6 M | Nasdaq Global Select Market | ||
|
Zai Lab Limited
ZLAB
|
$ 22.11 | -6.03 % | $ 24.2 B | Nasdaq Global Select Market | ||
|
Verrica Pharmaceuticals
VRCA
|
$ 2.9 | -7.64 % | $ 30.9 M | Nasdaq Global Market | ||
|
Wave Life Sciences Ltd.
WVE
|
$ 2.77 | -2.64 % | $ 467 M | Nasdaq Global Select Market | ||
|
Zymeworks
ZYME
|
$ 26.04 | 0.77 % | $ 1.34 B | NYSE | ||
|
XBiotech
XBIT
|
$ 1.76 | -1.12 % | $ 53.7 M | Nasdaq Global Select Market | ||
|
XTL Biopharmaceuticals Ltd.
XTLB
|
$ 1.54 | -4.94 % | $ 1.04 B | Nasdaq Capital Market | ||
|
Vertex Pharmaceuticals Incorporated
VRTX
|
$ 536.27 | 0.39 % | $ 137 B | Nasdaq Global Select Market,SPB | ||
|
Adial Pharmaceuticals
ADIL
|
$ 3.15 | -35.42 % | $ 2.11 M | Nasdaq Capital Market | ||
|
ADMA Biologics
ADMA
|
$ 13.56 | -0.51 % | $ 3.23 B | Nasdaq Global Market | ||
|
Exicure
XCUR
|
$ 1.08 | 2.74 % | $ 6.8 M | Nasdaq Capital Market | ||
|
Xencor
XNCR
|
$ 34.28 | -0.64 % | $ 2.54 B | Nasdaq Global Select Market,SPB | ||
|
Cortexyme
CRTX
|
- | -1.05 % | $ 67.1 M | Nasdaq Global Select Market,SPB | ||
|
Burford Capital Limited
BUR
|
$ 3.69 | 2.36 % | $ 809 M | NYSE | ||
|
Daré Bioscience
DARE
|
$ 0.45 | 4.92 % | $ 5.03 M | Nasdaq Capital Market | ||
|
Fate Therapeutics
FATE
|
$ 1.05 | 2.94 % | $ 125 M | Nasdaq Global Market,SPB | ||
|
Greenwich LifeSciences
GLSI
|
$ 20.57 | 10.01 % | $ 278 M | Nasdaq Capital Market | ||
|
Halozyme Therapeutics
HALO
|
$ 95.8 | -0.18 % | $ 11.5 B | Nasdaq Global Select Market,SPB | ||
|
Hutchison China MediTech Limited
HCM
|
$ 13.95 | -3.12 % | $ 12 B | Nasdaq Global Select Market | ||
|
Aptorum Group Limited
APM
|
- | - | $ 5.72 M | Nasdaq Global Select Market | ||
|
iBio
IBIO
|
$ 0.82 | 9.38 % | $ 85.3 M | NYSE American | ||
|
Kodiak Sciences
KOD
|
$ 97.66 | 0.89 % | $ 5.2 B | Nasdaq Global Market,SPB | ||
|
Karyopharm Therapeutics
KPTI
|
$ 0.02 | -56.5 % | $ 219 | Nasdaq Global Select Market | ||
|
FSD Pharma
HUGE
|
- | 5743.5 % | $ 69.7 M | Nasdaq Capital Market | ||
|
BioAtla
BCAB
|
$ 1.74 | 0.64 % | $ 102 M | Nasdaq Global Select Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.